Johnson & Johnson (JNJ) said Sunday that results from a phase 2 trial of its experimental combination of Talvey and Tecvayli showed a nearly 79% overall response rate with durability in patients with a certain type of cancer.
The results cover patients with triple-class exposed relapsed or refractory multiple myeloma who have true extramedullary disease.
The company said that 54% of the patients achieved a complete response or better in the study. Results from responders indicated "deep and durable" responses, the company said.
Treatment with the combination led to 61% of patients progression free and alive at one year, Johnson & Johnson said.
Extramedullary disease represents an aggressive form of multiple myeloma.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。